Newsletter free until November → Subscribe
Classy AI News
Subscribe

Biotech archive

Every Biotech story, newest first. 88 in this archive.

Biotech this week

  1. Aug 29, 2026

    Ainnocence Reports AINN P1 Lifts Antibody Affinity Ranking by 28 Percent

    Ainnocence reports its frozen AINN P1 encoder lifted antibody antigen affinity ranking correlation by about 28 percent over a from scratch baseline in cross validation. Teams should wait for prospective lab validation before changing lead rules.

  2. Aug 28, 2026

    AutoBinder Agent Unifies Protein Binder Design Through MCP Tool Orchestration

    AutoBinder Agent uses MCP to orchestrate MaSIF, Rosetta, ProteinMPNN, and AlphaFold3 into one reproducible protein binder design workflow.

  3. Aug 28, 2026

    Insilico Moves Rentosertib Into Phase III as First Fully AI Originated Drug at That Stage

    The Chinese biotech says its TNIK inhibitor for idiopathic pulmonary fibrosis cleared Phase IIa with a forced vital capacity signal strong enough to start a 320 patient pivotal program.

  4. Aug 26, 2026

    Genentech Validates First AI Surfaced Neuroscience Target From Recursion Deal

    Genentech exercised a validated target option on a previously unexplored neuroscience target discovered through Recursion Pharmaceuticals phenomics platform, advancing it into small molecule early discovery.

  5. Aug 24, 2026

    Claude Designed Working Protein Binders on 14 of 15 Lab Targets

    Anthropic said Claude designed binders for 14 of 15 protein targets with 22 to 35 percent hit rates, validated by Adaptyv Bio and Twist Bioscience, plus fast NMR and LC MS analysis.

  6. Aug 24, 2026

    Chai Discovery Partners With BMS to Generate Antibodies From Scratch

    Chai Discovery partnered with Bristol Myers Squibb to apply its generative AI antibody design platform across BMS's portfolio, adding a fifth major pharma deal for the startup after its $400 million Series C.

  7. Aug 17, 2026

    175 AI Drug Programs Have Entered Trials but Zero FDA Approvals So Far

    Roughly 175 AI originated drug programs have entered human trials but zero hold full FDA approval as of August 2026, putting the verification era ahead of the hype cycle.

  8. Aug 16, 2026

    Benchling Report Maps Biotech Shift Into the AI Builder Phase

    Benchling's 2026 survey of about 100 R&D organizations finds biotech entering a builder phase led by internal upskilling, embedded AI leadership, and integrated data infrastructure.

  9. Aug 15, 2026

    Insilico's DDD Benchmark Asks the Question Pharma Cannot Ignore: Can AI Actually Discover Drugs?

    Insilico Medicine's DDD Benchmark as a Service tests frontier models on decontaminated, real-world drug discovery tasks — 300+ evaluations and full-program PCC scenarios.

  10. Aug 14, 2026

    Recursion's First Genentech-Validated Neuro Target Enters Early Discovery — With $3M Milestone Attached

    Genentech exercised the first validated target option from its Recursion phenomap collaboration, advancing a previously unexplored neuroscience target into early discovery with a $3M milestone.

  11. Aug 13, 2026

    Qu-Net at USC: Quantum-Enhanced AI Draws Sharper Tumor Boundaries With Fewer Parameters

    USC's Qu-Net hybrid system beats classical U-Net on medical image segmentation with one-sixth the parameters—and is moving toward clinical radiation oncology testing.

  12. Aug 12, 2026

    Insilico’s H1 Profit Alert Pairs Revenue Surge With Phase III Rentosertib and Agentic Lab Stack

    Insilico’s July 8, 2026 profit alert projects up to ~287% H1 revenue growth alongside Phase III Rentosertib, new clinical programs, and agentic lab platforms—while stressing all assets remain investigational.

  13. Aug 11, 2026

    Insilico Nominates AI-Designed ISM9077 for Ocular Disease With Eye-Drop Ambitions

    Insilico Medicine nominated AI-designed ISM9077 for dry AMD, uveitis, and dry eye, reporting strong preclinical signals and eye-drop formulation potential — its 32nd preclinical candidate since 2021.

  14. Aug 10, 2026

    Evotec and Odyssey Link AI Screening to Validated Hit Series in Autoimmune Discovery

    Evotec and Odyssey Therapeutics partner on AI-enabled small-molecule discovery in autoimmune disease, with milestone payments tied to validated hit series.

  15. Aug 9, 2026

    Chugai Deploys Phylo's Biomni Lab Agents Across Drug Discovery

    Chugai Pharmaceutical deploys Phylo's Biomni Lab agentic AI platform across preclinical drug discovery workflows, joining a wave of Japanese pharma enterprise adoptions.

  16. Aug 8, 2026

    Trials, Not Molecules: Pathos Routes Two Oncology Assets Through Foundry's Agent Stack

    Pathos AI pays $125M for Alphamab's dual-target ADC JSKN016 and takes early clinical development of AstraZeneca's AZD4241—both routed through Foundry's parallel agent platform to compress trial design, not just discovery.

  17. Aug 8, 2026

    Benchmarks Aren't Patients: Nature Reviews Drug Discovery Takes Stock of AI's Clinical Gap

    A Nature Reviews Drug Discovery Perspective published August 7 argues AI drug-discovery methods have advanced faster than clinically relevant impact — and urges decision-quality benchmarks.

  18. Aug 8, 2026

    37,000 Agents, One ADC: Stanford's Virtual Biotech and Merck's Independent Convergence

    James Zou's Virtual Biotech runs tens of thousands of agents across discovery divisions — and Merck's independent validation of an AI-designed CD276 ADC may be the first external proof point.

  19. Aug 7, 2026

    Agents Inside the Perimeter: Phylo and Chugai Deploy Biomni Lab Across Discovery Workflows

    Chugai Pharmaceutical deploys Phylo's Biomni Lab agentic AI across preclinical discovery workflows in an August 4, 2026 partnership.

  20. Aug 6, 2026

    Two UK Shops, One German Buyer: Merck's $1.3B AI Discovery Bet Tests the Phase III Clock

    Merck KGaA signs parallel Exscientia and BenevolentAI discovery deals worth up to $1.3B combined, layering external AI throughput onto its Addison and SYNTHIA in-house stack.